• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed

    2/26/21 12:15:16 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CBMG alert in real time by email
    EDGAR Filing Documents for 0001654954-21-001894
    Home | Latest Filings | Previous Page
    SEC Seal
    SEC Banner
    Search the Next-Generation EDGAR System
    Filing Detail
    • SEC Home »
    • Search the Next-Generation EDGAR System »
    • Company Search »
    • Current Page
    Form POS AM - Post-Effective amendments for registration statement:
    SEC Accession No. 0001654954-21-001894
    Filing Date
    2021-02-19
    Accepted
    2021-02-19 15:07:49
    Documents
    1

    Document Format Files

    Seq Description Document Type Size
    1 POS AM cbmg_posam.htm POS AM 36232
      Complete submission text file 0001654954-21-001894.txt   37371
    Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 100 ROCKVILLE MD 20850
    Business Address 9605 MEDICAL CENTER DRIVE SUITE 100 ROCKVILLE MD 20850 (301) 825 5320
    Cellular Biomedicine Group, Inc. (Filer) CIK: 0001378624 (see all company filings)

    IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
    Type: POS AM | Act: 33 | File No.: 333-227773 | Film No.: 21654788
    SIC: 2836 Biological Products, (No Diagnostic Substances)
    Office of Life Sciences

    Get the next $CBMG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBMG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBMG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jacky Gang Ji

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:13:16 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Alan Kwok Chun Au

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:13:22 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Yihong Yao disposed to the issuer $0 worth of Common Stock (18,900 units at $0.00) and was granted 54,000 units of Common Stock, decreasing ownership by 100% to 0 units

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:12:58 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellular Biomedicine Group, Inc. Announces Completion of Merger

    ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (the "Merger") of the Company with CBMG Merger Sub Inc., a Delaware corporation ("Merger Sub") and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company's stockholders at its special

    2/19/21 2:55:00 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger

    ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company's stockholders vote FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the "merger proposal").  The Company will hold a special meeting o

    1/28/21 4:30:00 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

    GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that three abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held as a virtual event on December 5-8, 2020. C-CAR088Abstract Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple MyelomaProgram: Oral and

    12/4/20 7:35:00 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    SEC Filings

    View All

    SEC Form 15-12G filed

    15-12G - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    3/3/21 2:40:08 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    2/26/21 12:15:06 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    2/26/21 12:15:16 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed

    SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)

    2/19/21 7:50:47 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)

    2/19/21 3:44:36 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care